Species specific optimization and development of rifamycins for the treatment of nontuberculous mycobacterial lung disease
|Effective start/end date||6/6/23 → 5/31/24|
- HACKENSACK MERIDIAN HEALTH, INC
- NATIONAL INSTITUTES OF HEALTH (NIH)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.